Comparative evaluation of two once-a-month contraceptive injections

Area of Science:

• Reproductive Health
• Endocrinology
• Pharmacology

Background:

• Once-a-month injectable contraceptives offer a convenient hormonal option for family planning.
• Evaluating the comparative effectiveness and tolerability of different formulations is crucial for clinical practice.

Purpose of the Study:

• To compare the efficacy, side effects, and discontinuation rates of two once-a-month injectable contraceptives: Cyclo-Provera and HRP-102.
• To assess the suitability of these preparations for national family planning programs.

Main Methods:

• A randomized allocation study involving 206 women over one year.
• Participants received either Cyclo-Provera (Depo-medroxy Progesterone Acetate 25 mg and Estradiol Cypionate 5 mg) or HRP-102 (Norethisterone enanthate 50 mg and Estradiol Valerate 5 mg).
• Data collected included efficacy, complaints, and reasons for discontinuation.

Main Results:

• Both Cyclo-Provera and HRP-102 showed high efficacy, with one pregnancy in the HRP-102 group (1.4% pregnancy rate).
• Little difference was observed in efficacy and side effects between the two preparations.
• Overall discontinuation rates at one year were similar: 57.6% for Cyclo-Provera and 54.9% for HRP-102, with bleeding irregularities being a primary reason.

Conclusions:

• Both once-a-month injectable contraceptives are highly effective and well-tolerated.
• These preparations can play a significant role in national family planning programs.
• Further research may explore long-term outcomes and patient satisfaction.